An enhanced bioavailable formulation of curcumin using fenugreek-derived soluble dietary fibre

Journal of Functional Foods

Volumn 4, Issue 1, 2012, Pages 348-357

  Krishnakumar, I M ^a   Ravi, Abhilash ^a   Kumar, Dinesh ^a   Kuttan, Ramadasan ^b   Maliakel, Balu ^a  

^a R and D Centre   (India)

^b AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Bioavailability; Controlled release; Curcumin; Fenugreek; Soluble fibre; Ultrasound

Indexed keywords

ANIMALIA; CURCUMA LONGA; RATTUS NORVEGICUS; TRIGONELLA FOENUM-GRAECUM;

EID: 84857690182     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2012.01.004     Document Type: Article

References (38)

1. Abe Y., Hashimoto S., Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacological Research 1999, 39:41-47.
2. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Research 2003, 23:363-398.
3. Aggarwal B.B., Kumar A., Aggarwal M.S., Shishodia S. Phytopharmaceuticals in cancer chemoprevention 2004, 349-387. CRC Press, Boca Raton, FL. D. Bagchi, H.G. Preus (Eds.).
4. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 2007, 4:807-818.
5. Antony, B. Composition to enhance the bioavailability of curcumin. US patent: 2008/0226755 A1.
6. AOAC official methods of analysis 2000 ed., Method No. 985.29, Enzymatic gravimetric analysis (p. 78).
7. Arun N., Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods for Human Nutrition 2002, 57:41-52.
8. Boban P.T., Nambisan B., Sudhakaran P.R. Hypolipidaemic effect of chemically different mucilage's in rats: A comparative study. British Journal of Nutrition 2006, 96:1021-1029.
9. Burke M.D., Park J.O., Srinivasarao M., Khan S.A. A novel enzymatic technique for limiting drug mobility in a hydrogel matrix. Journal of Controlled Release 2005, 104:141-153.
10. Chan M.M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochemical Pharmacology 1995, 49:1551-1556.
11. Deodhar S.D., Sethi R., Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian Journal of Medical Research 1980, 71:632-634.
12. Dorai T., Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Letters 2004, 215:129-140.
13. Evans A.J., Hood R.L., Oaken full D.G., Sidhu G.S. Relationship between structure and function of dietary fibre: A comparative study of the effects of three galactomannans on cholesterol metabolism in the rat. British Journal of Nutrition 1992, 68:217-229.
14. Funk J.L., Oyarzo J.N., Frye J.B., Chen G., Lantz C., Jolad S.D., Aniko M., Solyom A.M., Timmermann B.N. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. Journal of Natural Products 2006, 69:351-355.
15. Hannan J.M., Rokeya B., Faruque O., Nahar N., Mosihuzzaman M., Azad Khan A.K., Ali L. Effect of soluble dietary fibre fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet aggregation status of Type 2 diabetic model rats. Journal of Ethnopharmacology 2003, 88:73-77.
16. Hiroki S., Yoichi S., Kenji T., Atsushi I., Hiroyuki F., Tadashi H., Hiromichi W., Yasufumi K., Hideaki K., Masatoshi F., Koji H., Tatsuya M. Innovative preparation of curcumin for improved oral bioavailability. Biological and Pharmacological Bulletin 2011, 34:660-665.
17. Holt P.R., Katz S., Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Digestive Diseases and Sciences 2005, 50:2191-2193.
18. Hsu C.H., Cheng A.L. Clinical studies with curcumin. Advances in Experimental Medicine and Biology 2007, 595:471-480.
19. Huang M.T., Lysz T., Ferraro T. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Research 1991, 51:813-819.
20. JECFA. (2003). published in FNP 52 Add 11 (2003), superseding specifications prepared at 57th JECFA (2001) and published in FNP 52 Add 9 (2001).
21. Jobin C., Bradham C.A., Russo M.P. Curcumin blocks cytokine-mediated NF-ka B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kB kinase activity. Journal of Immunology 1999, 163:3474-3483.
22. Kiso Y., Suzuki Y., Watanabe N., Oshima Y., Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Medica 1983, 49:185-187.
23. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters 2008, 269:199-225.
24. Lao C.D., Ruffin M.T., Normolle D., Heath D.D., Murray S.I., Bailey J.M., Boggs M.E., Crowell J., Rock C.L., Brenner D.E. Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine 2006, 6:10.
25. Li M., Zhang Z., Hill D.L., Wang H., Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Research 2007, 67:1966-1968.
26. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemotherapy Pharmacology 2007, 60:171-177.
27. Nirmala C., Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Molecular and Cellular Biochemistry 1996, 159:85-93.
28. Nokhodchi A., Nazemiyeh H., Khodaparast A., Sorkh-Shahan T., Valizadeh H., Ford J.L. An in vitro evaluation of fenugreek mucilage as a potential excipient for oral controlled-release matrix tablet. Drug Development and Industrial Pharmacy 2008, 34:323-329.
29. Patel M., Patel S., Bhadani M., Shah T., Amin A. A synchronous colon-specific drug delivery system for orally administered mesalamine. Acta Pharmaceutica Sciencia 2009, 51:251-260.
30. Ruby A.J., Kuttan G., Babu K.D., Rajasekharan K.N., Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Letters 1995, 94:79-83.
31. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clinical Cancer Research 2004, 10:6847-6854.
32. Sinha V.R., Rachna K. Polysaccharides in colon-specific drug delivery. International Journal of Pharmaceutics 2001, 224:19-38.
33. Srivastava M., Kapoor V.P. Seed galactomannans: An overview. Chemistry & Biodiversity 2005, 2:295-317.
34. Srivastava R., Dikshit M., Srimal R.C., Dhawan B.N. Antithrombotic effect of curcumin. Thrombosis Research 1985, 40:413-417.
35. Surh Y.J., Chun K.S., Cha H.H. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NFkB activation. Mutation Research 2001, 243:480-481.
36. Venkatesan N., Punithavath D., Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. British Journal of Pharmacology 2000, 129:231-234.
37. Yang F., Lim P.G., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry 2005, 280:5892-5901.
38. Zheng Z., Zhang X., Carbo D., Clark C., Nathan C.A., Lvov Y. Sonication-assisted synthesis of polyelectrolyte-coated curcumin nanoparticles. Langmuir 2010, 26:7679-7681.